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Background: Thestratumcorneum(SC) formsadifficultphysicalbarrier fordrugs topass through theskin.Several strat-
egieswere developed to overcome this barrier. Optimization of topical drug formulations by selected excipientsmay fa-
cilitate the penetration of drugs through the SC into the viable skin cells and ultimately into the systemic circulation.
Methods:Here, both the influence of two formulations (a classic carbomer-based gel and a novel Pluronic lecithin
organo gel (PLO gel)) and selected excipients (ethanol, propylene glycol, diethylene glycol monoethyl ether, iso-
propyl myristate (IPM), and water) with or without the penetration enhancer miconazole nitrate on the transder-
mal penetration characteristics of caffeine were determined using an in vitro Franz diffusion cell setup.
Results:Higher fluxes were observed for the carbomer-based gel compared to the PLO gel. Among the commonly
used excipients, IPM showed the best penetration enhancing properties, while the presence of the penetration en-
hancer miconazole nitrate did not significantly alter the apparent skin permeation characteristics for caffeine.
Conclusion: The high ethanol percentage in the carbomer-based gel could explain the results as supported by our
excipient data. Moreover, IPM could play a beneficial role in topical formulations as this excipient was responsible
for a significant increase in the amount of caffeine penetrated through the skin. No overall statistical significant
effect of the presence of miconazole nitrate as a penetration enhancer was observed.
Introduction
The skin as a route for drug administration has becomevery attractive. Transdermal drug delivery offers several
other advantages in comparison with the traditional oral
route of administration, such as minimization of the first
pass effect and avoidance of the acidic environment of the
stomach, which could be responsible for drug degradation.
This results in a higher bioavailability of the drug, decreased
side effects, and more stable plasma levels. Transdermal drug
delivery also provides more controlled long-term drug deliv-
ery1,2 and represents a noninvasive route of administration,
which can result in improved patient adherence.3
Topical administration of caffeine can be used both for local
as well as for a systemic activity. Moreover, the internationally
accepted guidelines 427 and 428 from theOrganization for Eco-
nomicCo-operation andDevelopment (OECD) recommend the
use of caffeine as a model compound in skin research.4,5
Skin transport of drugs can be investigated using in vivo
studies with humans and are considered to be the gold stan-
dard. However, for ethical reasons, the ex vivo/in vitro meth-
ods, using excised human or animal skin are more frequently
used. The skin can be seen as a homogeneous brick andmortar
model (i.e., stratum corneum (SC) corneocytes with surround-
ing lipids) with an underlying viable epidermis consisting of
different strata and the dermis. Herein, the SC is a difficult bar-
rier to overcome. Optimization of the topically applied formu-
lation can improve the release of the active drug to and
through the skin. A classic strategy for modifying the skin bar-
rier function is the use of selected excipients. The aim of this
study was to examine whether the two topical formulations
and selected topical excipients, with or without the recently
discovered penetration enhancer miconazole nitrate,6 have an
influence on the transdermal behavior of caffeine.
Materials and Methods
Products examined
Caffeine (Ph. Eur. grade) was obtained from ABC Chemi-
cals (Vemedia, Wouters-Brakel, Belgium) or from Ludeco
(Sint-Gillis, Belgium). Miconazole nitrate (MN) was also
bought from ABC Chemicals (Vemedia, Wouters-Brakel,
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Belgium). The Pluronic lecithin organo gel and the carbomer-
based gel were prepared by the Laboratory of Pharmaceutical
Technology (Faculty of Pharmaceutical Sciences, Ghent,
Belgium). The PLO gel consisted of 1 g of caffeine, 19 g of
the lecithin solution (Fagron, Waregem, Belgium; content: lec-
ithin, isopropyl palmitate, and potassium sorbate), and 80g of
the Pluronic gel (Fagron, Waregem, Belgium; content: Plur-
onic F127 (Poloxamer 407), potassium chloride, potassium
sorbate, sodium benzoate, and cold water), while the carbomer
gel consists of 1 g of caffeine, 12g of propylene glycol (PG), 3g
of carbomer 980, and 84g of ethanol (96% V/V).
Chemicals and reagents
About 0.01M phosphate-buffered saline (PBS) was pre-
pared according to the instructions of the supplier (Sigma,
St. Louis, MO). Ultrapure water (H2O) of 18.2MO.cm quality
was obtained by using an Arium 611 purification system (Sar-
torius, Go¨ttingen, Germany). High-performance liquid chro-
matography (HPLC), gradient grade methanol (MeOH),
and acetonitrile (ACN) were purchased from Fisher Scientific
(Leicestershire, United Kingdom). Formic acid (FA) and PG
were obtained from Riedel-de Hae¨n (Seelze-Hannover, Ger-
many). Denaturated ethanol (up to 5% ether) was obtained
from Chem Lab (Zedelgem, Belgium), while absolute ethanol
(EtOH, 99.8% V/V) was obtained from Sigma. Diethylene
glycol monoethyl ether (DGME) and isopropyl myristate
(IPM) were bought from Fluka (Steinheim, Germany) and hy-
drogen chloride (HCl) from Acros organics (Geel, Belgium).
Preparations of saturated solutions
and solubility determination
An excess amount of caffeine (n = 2–3) was added to each
excipient (EtOH, PG, DGME, IPM, H2O, 50:50 EtOH:H2O)
and subsequently incubated for 24 hours at 32C (skin surface
temperature4), while shaking on a laboratory Eppendorf
Thermo mixer at 1000 rpm. Vortex mixture was done at
regular time points. After incubation, the samples were
centrifuged with an Eppendorf 5417R centrifuge (Hamburg,
Germany) for 10 minutes at 20,000 g, while keeping the tem-
perature at 32C. The clear supernatant was collected and im-
mediately diluted with the appropriate mobile phase (20:80
ACN:H2O (V/V)). The concentration of caffeine was deter-
mined in the resulting solution using a validated HPLC-UV
method (see 2.5.). Due to incompatibility of IPM with the
HPLC mobile phase, solubility data of caffeine in IPM were
obtained from UV/VIS spectra at 273 nm (Ultrospec 4000
Pharmacia Biotech UV/VIS spectrophotometer, England).
Preparation of Franz diffusion cell dose solutions
The gel formulations. To investigate the effect of the used
formulation on the transdermal behavior of caffeine, 600mg
of the PLO gel and carbomer-based gel, each containing 1%
caffeine, were topically applied to the epidermal surface of
the skin in a Franz diffusion cell (FDC) setup.
Caffeine dose solutions in different excipients. Dose solu-
tions were prepared with caffeine to obtain a 2mg/mL caf-
feine solution with or without 1.0 · 105 M miconazole
nitrate.6 Due to limited solubility of caffeine in IPM, a
0.4mg/mL caffeine (–MN) IPM-dose solution was prepared.
High-performance liquid chromatography
Caffeine in the different FDC samples was analyzed using
a validated high-throughput HPLC-UV method. The HPLC
apparatus consisted of a Waters Alliance 2695 separation
module and a dual absorbance detector 2487 equipped with
Empower 2 software (all Waters, Millford, PA). About 20lL
of each sample was injected on a Lichrospher 100 RP C18 col-
umn (125mm · 4mm, 5lm particle size) (Merck, Darmstadt,
Germany) with an appropriate guard column. The sample
compartment was kept constant at 15C, while the column
temperature was maintained at 30C. The flow rate was set
at 1mL/min. A degassed isocratic mobile phase consisting
of 83:17A:B (V/V, A: 0.1% FA in H2O, B: 0.1% FA in ACN)
or 75:25 A:C (V/V, C: 0.1% FA in MeOH) were used for the
caffeine determination in the excipients and gels experiment,
respectively. UV detection was performed at 273 nm.
In vitro permeation study
The skin permeation of caffeine in the different dose for-
mulations was determined using static FDCs (Logan Instru-
ments Corp.) with a receptor compartment of 5mL and
an available diffusion area of 0.64 cm2. The analyses were
minimally done in duplicate using human skin in a random-
ized blocked design, that is, same skin donor sample (cut in
several small FDC pieces) was used for the different formula-
tions during one experimental run. The skin samples, sup-
plied by the University Hospital (Ghent, Belgium), were
obtained after a cosmetic reduction surgery from a healthy
male patient (59 years) and from three healthy females
(48 – 7 years old, mean– SD), to incorporate possible gender
variability,7–9 with informed consent and confidentiality
procedures in place. Subsequently, the skin was cleaned
with 0.01M PBS pH 7.4 and the subcutaneous fat was re-
moved. The skin was then stored at 20C for not longer
than 6 months. Just before the start of the FDC experiments,
the full-thickness skin was thawed, mounted on a tem-
plate, and dermatomed using an electrical powered derma-
tome to obtain a skin thickness of approximately 400 lm.
An actual skin thickness of 380– 11lm (mean– SEM, n = 25),
277– 16lm (mean– SEM, n= 18), 421– 19lm (mean– SEM,
n = 20), and 368– 27 (mean– SEM, n = 20) lm was experimen-
tally determined with a micrometer (Mitutoyo, Tokyo, Japan)
from different patients. Each receptor chamberwas filledwith
0.01M PBS. The skin samples were visually inspected for skin
damage and were mounted on the FDC between the donor
and the receptor chambers, with the epidermis upward, tak-
ing care that no air under the skin was present. The recep-
tor fluid was continuously mixed using a Teflon-coated
magnetic stirring bar (400 rpm). Skin integrity was checked
by measuring the skin impedance using an automatic micro-
processor controlled Tinsley LCR Impedance Bridge (Croy-
don, United Kingdom). Skin pieces with an impedance
value below 10kO were discarded and replaced by a new
skin piece.10 Approximately 600mg of the gels or 500lL of
the excipient-dose solutions were topically applied on the
skin surface with a syringe or micropipette, respectively. To
prevent evaporation of the dose formulations, the donor
chamber was covered with parafilm (American National
Can, Chicago, IL). During the experiment, the temperature
of the receptor compartment was kept constant at 32C by a
water jacket. About 200lL samples of receptor fluid were
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taken at regular time intervals up to 24 hours from the sample
port and were immediately replaced by 200lL fresh receptor
fluid. This was taken into account in the cumulative concen-
tration calculations. Immediately after the last sample had
been drawn (i.e., after 24 hours), the remaining dose formula-
tion was removed from the skin surfaces using a cotton swab
and caffeine was extracted from the skin with ethanol. A lin-
ear relationship of the individual cumulative amounts of caf-
feine versus time was observed and steady-state and sink
conditions were confirmed by our data.
Calculation of skin permeation parameters
The cumulative amount of caffeine (in lg) permeated
through human skin was plotted as a function of time (in
hours). Steady-state flux ( Jss, lg/cm
2.h) was calculated
from the slope of the linear portion of the cumulative amount
versus time curve divided by 0.64 (exposed skin area in cm2).
By setting y = 0 in the individual linear regression equation,
the lag time (h) was obtained. From these secondary param-
eters, the primary parameters are calculated in accordance
with ECETOC, CEFIC11: the permeability coefficient (Kp,
cm/h) could be calculated as follows:
Kp¼ Jss
cd
where Cd (lg/mL) is the concentration of caffeine in the dose
formulation. Moreover, the apparent diffusion (Dm, cm
2/h)








where d and tlag are the measured skin thickness (cm) and the
lag time (h), respectively.
Results
Influence of the formulation on the transdermal
behavior of caffeine
The flux curves of caffeine in the carbomer and PLO gel are
presented in Figure 1.
Secondary and primary transdermal parameters were cal-
culated from the linear regression data. A higher flux and
resulting permeability coefficient Kp for caffeine was ob-
served with the classic carbomer-based gel compared to the
PLO gel (Fig. 2).
Not only the Dm of caffeine formulated in the carbomer gel
was higher than in the PLO gel (Fig. 3), indicating the formu-
lation composition most probably changed the structure of
the skin, but also the partitioning of caffeine from the
carbomer gel was higher compared to the PLO gel.
Solubility data of caffeine in the different excipients
The solubility of caffeine at 32C (S32C) in the different ex-
cipients was determined in triplicate. The results are shown
in Table 1.
Excipient effects on the transdermal behavior of caffeine
The primary transdermal parameters for caffeine solubi-
lized in the different topical excipients ( –MN) are given in
Table 2.
The choice of excipients had a major influence on the trans-
dermal characterization of caffeine: in IPM, caffeine showed a
significant Kp increase compared to the other excipients
(Table 2). While the diffusion coefficient obtained with IPM
was comparable to the other Dm values, the Km was notice-
able higher, indicating that caffeine was more partitioned
into the skin from the IPM dose solution compared to other
excipients. Overall, no statistically significant effect of MN
could be demonstrated on the Kp of caffeine (paired t-test:
t= 0.791, df = 5, 0.465 significance), consistent with our pre-
vious observations,6 although small effects for individual ex-
cipients cannot be ruled out in the case of pure EtOH, H2O,
and IPM.
Discussion
The way of drugs in a topical formulation to pass through
the skin is governed by the partition (mainly between dose
solution and SC) and diffusion processes through the differ-
ent layers constituting the heterogeneous skin. Apparent
FIG. 1. Cumulative amount of drug in the receptor fluid
after application of caffeine in the carbomer and PLO gel on
isolated human skin (n= 3, mean – SEM). PLO, Pluronic lec-
ithin organo gel.
FIG. 2. Permeability coefficient of caffeine in the investi-
gated gels (n= 3, mean– SEM).
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transdermal parameters reflecting these two processes (i.e.,
partition coefficient Km and diffusion coefficient Dm) can be
experimentally determined. Hansen et al.12 collected the com-
plete data set for caffeine (molecular weight = 194.2 g/mol,
log Koct/H2O=0.083, pKa = 1.39). From aqueous donor solu-
tions, caffeine shows a clear partitioning into the SC. Caffeine
prefers to stay in the SC environment in contrast to the more
hydrophilic viable skin layers in which caffeine does not bind
to the proteins present in these layers.12 This is consistent
with the low-affinity binding of caffeine for human serum al-
bumin.13 However, caffeine can reach the systemic circulation
after topical application. In vivo studies with human volun-
teers using the follicle closure technique have shown that caf-
feine (formulated as 2.5% (m/V) caffeine, 30% ethanol, and
70% PG) reached the blood after only 5 minutes through
the hair follicle pathway.14,15
In this study, the influence of two gel formulations on the
transdermal penetration characteristics of caffeine was inves-
tigated.16 The Pluronic lecithin organo gel is a phospholipi-
dic polymeric topical gel, recently developed and marketed
for transdermal applications, claiming enhanced skin perme-
ation and absorption of drugs17,18 with lecithin acting as a
penetration enhancer on the skin. The carbomer gel is a classic
base, which often contains a high percentage of ethanol
as well as PG, well-known skin penetration enhancers. Etha-
nol can cause an increased permeation of model drugs.19
Hence, our results with the carbomer-based gel having signif-
icant caffeine penetration through the skin can be ascribed to
the influence of ethanol, acting as a chemical penetration en-
hancer. Ethanol is considered a pharmacologically inactive
compound in a topical formulation, but it increases skin per-
meability by interacting with the SC constituents.20,21 Next to
purely solubility considerations, several skin-related mecha-
nisms of actions are described for penetration enhancers: (1)
disruption of the SC lipid organization, by incorporation in
the bilayer to increase the free volume for drug diffusion.
(2) Interaction with keratin and creation of a less dense pro-
tein structure to make it more permeable. (3) Interactions
with desmosomes to alter the cohesion between corneocytes.
(4) Changing the environment in the bilayer and thereby
changing the solubility properties, leading to an increase in
partition coefficient.22 It is likely that penetration enhancers
like ethanol work through various mechanisms.19,23
To evaluate the observed effects in the comparison of the
PLO versus the carbomer gel, the penetration behavior of caf-
feine in different solvents was studied. Ethanol and PG are
examples of solvents that can increase the drug solubility in
the skin.19,21 Improvement of transdermal parameters was
observed for the 50:50 EtOH:H2O formulation compared to
the pure 100% EtOH, which confirms the penetration en-
hancement effect of ethanol in the presence of water on caf-
feine, which is a hydrophilic compound.24 From Table 2, it
is observed that the Kp for caffeine in PG is very low. PG
only acts as a penetration enhancer for drugs that are more
soluble in alcohol than in water.24 Caffeine is sparingly
soluble in water and slightly soluble in ethanol (96%).25
These are not the optimal conditions for PG as a penetration
enhancer, consistent with the low transdermal parameters
found in this study. DGME is described in the literature as
a nontoxic strong solubilizing agent that can act as a penetra-
tion enhancer.24 The relatively low transdermal parameter
values are probably due to the fact that DGME should be
used in combination with appropriate cosolvents.26
The penetration-enhancing properties of IPM were con-
firmed by the high transdermal flux values of caffeine
through the skin. IPM can partition into both the lipid and
protein areas of the skin27 and recent studies indicate that
IPM disturbs the multilamellar lipid assembly.28 Moreover,
after its incorporation into the SC lipids, IPM will also extract
certain SC lipids into a separate phase. These effects all lead to
a liquefaction of the SC lipids, accounting at least partly for
the enhancing activities of IPM. Schwarb et al.29 investigated
the effect of the degree of saturation of donor solutions on
in vitro silicone membranes. They found that with the increas-
ing thermodynamic activity (supersaturation) of the applied
vehicle, the in vitro diffusion coefficient across the membrane
was increased. When the saturation solubility of a compound
in the donor solution increases and the saturation solubility of
FIG. 3. Diffusion (left) and
distribution (right) coefficient
of caffeine in the gels (n = 3,
mean – SEM).
Table 1. S32C of Caffeine in the Selected Excipients







EtOH 163.29– 1.27 Slightly soluble
PG 84.75– 0.24 Sparingly soluble
DGME 66.58– 0.54 Sparingly soluble
IPM 1102.85– 2.12 Very slightly soluble
H2O 33.02– 2.36 Sparingly soluble
50:50 EtOH:H2O
(V/V)
9.09 – 1.21 Freely soluble
EtOH, ethanol; PG, propylene glycol; DGME, diethylene glycol
monoethyl ether; IPM, isopropyl myristate; H2O, water.
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the membrane remains constant, the partition coefficient will
decrease. In this study, the caffeine concentration used was
0.4mg/mL in IPM and 2mg/mL in the other excipients.
From Table 1, it is clear that the solubility of caffeine in IPM
is the lowest, while the used concentration of 0.4mg/mL
showed the highest thermodynamic activity. This can also
partly contribute to the high Kp value of caffeine in IPM. It
should be mentioned, however, that the uniform silicone
membrane as used by Schwarb et al.29 differs from the hetero-
geneous skin with its different layers as used in this study.
Besides the use of excipients with chemical penetration-
enhancing properties, other strategies for enhancing the
skin penetration are also available, such as microemulsions,
liposomal-based delivery systems, microneedles, electropora-
tion, supersaturated formulations, iontophoresis, sonophore-
sis, electroporation, and the use of nano- and microparticles
as carriers for drugs.21,30,31
Conclusion
No increase in transdermal flux of caffeine was observed
with the recently developed PLO gel compared to the classic
carbomer-based gel formulation. The carbomer formulation
consisted of a higher percentage of ethanol, which is a well-
known penetration enhancer, and which could explain the
results as supported by our excipient data. Moreover, IPM
showed a significant increase in the amount of caffeine pene-
trated through the skin, suggesting its beneficial role in topi-
cal caffeine formulations. No overall statistical significant
effect of the presence of miconazole nitrate as a penetration
enhancer was observed.
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